Pfizer: Buy Before The Street Catches Up To Its Own Numbers

Summary Pfizer is rated buy, not for deep value, but due to a disconnect between management's bullish long-term growth guidance and a flat consensus earnings curve. Consensus models a permanent post-2026 revenue/EPS decline, but PFE's $13B product base is compounding at 20%+, and the Vyndamax settlement secures $2–3B annual revenue through 2031. Management guides to high single-digit revenue CAGR from 2028 to 2033, implying 2033 revenue of $21–26B above even the Street's highest estimate. The downside appears fully priced; the upside lies in consensus upward revisions as out-year earnings recover, with no need for multiple expansion to drive returns. JHVEPhoto/iStock Editorial via Getty Images Most of the bullish work on Pfizer ( PFE ) this year has been built on the same argument that the stock is historically cheap. But I don’t think this holds up against the company's own This article was written by Justin Miller 46 Followers Follow I'm a data analyst working in the diagnostics and telehealth industry, and I write about what I know best, pharma, biotech and healthcare stocks. A few years back I started thinking seriously about long term investing for the future and the idea of retiring early. So I started learning everything I could about investing. What pulled me in was going deep on sectors and companies I already knew by name but didn’t really understand from the inside, not as products or headlines, but as businesses. The more I dug, the more I learned and the research paid me pretty well in terms of gains from those investments. There's a real reward in doing the work, getting to know a company inside out and finding the ones genuinely worth holding for the long haul. I am a numbers person so I try to keep my analysis grounded in data rather than hype. I also just enjoy the process of journaling and writing too. My goal here is simply to share my takes on healthcare names, dig into the stuff headlines tend to skip and trade ideas with people. Analyst’s Disclosure: I/we have a beneficial long position in the shares of PFE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.